A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Overview

This will be a single-dose, randomized, double-blind, active- and placebo-controlled, double dummy, 6-way crossover study to determine the abuse potential of tozadenant relative to d-amphetamine and placebo, when administered orally in healthy non-dependent, recreational polydrug users with stimulant experience, under fed conditions. Each subject will participate in a medical Screening visit, a 4-day (3-night) qualification (drug discrimination) visit, six 3-day (2-night) treatment periods, and a follow-up visit.

Full Title of Study: “A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Conditions”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Other
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: November 28, 2017

Detailed Description

The Qualification Phase will be conducted as a single, 4-day visit. Doses will be administered in a randomized, double-blind crossover manner following administration of a standard low-fat meal. Subjects will be dosed with 20 mg of d-amphetamine or matching placebo d-amphetamine on Day 1 and Day 2, approximately 24 hours apart. PD assessments will be conducted before dosing and at time points for up to 8 hours post dosing. Safety assessments will be conducted before dosing and for at least 24 hours following dosing. Data will be reviewed to determine subject eligibility. The last drug administration in the Qualification Phase and the first drug administration in the Treatment Phase will be separated by a washout interval of at least 7 days and not to exceed 28 days. During the Treatment Phase, there will be 6 treatment periods; subjects will receive a single oral dose of each of the following treatments with applicable matching oral placebos in a randomized, double-blind, double-dummy fashion following the administration of a standard, low-fat meal. The following treatments will be administered: – Treatment A: placebo (matched to tozadenant and d-amphetamine) – Treatment B: tozadenant 120 mg – Treatment C: tozadenant 240 mg – Treatment D: tozadenant 480 mg – Treatment E: d-amphetamine 20 mg – Treatment F: d-amphetamine 40 mg Drug administration will occur on Day 1 of each of the 6 treatment periods. PD and PK assessments will be collected during the 24 hours post-dose and safety assessments will be collected during the 36 hours post-dose. Subjects will be discharged on Day 2, after approximately 36 hours post-dose, or remain at the clinical research unit longer (e.g., 48 hours or until the following morning) if there are safety concerns, at the discretion of the investigator or designee. Drug administration in each treatment period will be separated by a washout interval of at least 7 days after the last dose of study drug. Subjects will return for an end-of-study safety Follow-up visit approximately 7 to 14 days after the subject's last study drug dose in the Treatment Phase or following early withdrawal.

Interventions

  • Drug: Tozadenant
    • 2, 4, 6 or 8 Tozadenant 60 mg tablets
  • Drug: Placebo oral tablet
    • 2, 4, 6 or 8 Tozadenant matching placebo tablets
  • Drug: d-amphetamine
    • 2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
  • Drug: Placebo oral capsule
    • 2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet

Arms, Groups and Cohorts

  • Placebo Comparator: Treatment A
    • Placebo oral tablet and Placebo oral capsule
  • Experimental: Treatment B
    • Tozadenant 120 mg
  • Experimental: Treatment C
    • Tozadenant 240 mg
  • Experimental: Treatment D
    • Tozadenant 480 mg
  • Active Comparator: Treatment E
    • d-amphetamine 20 mg
  • Active Comparator: Treatment F
    • d-amphetamine 40 mg

Clinical Trial Outcome Measures

Primary Measures

  • Drug Liking
    • Time Frame: 24 hours
    • Drug Liking Visual Analog Scale (VAS) (“at this moment”), assessed on a bipolar, 0- to 100-point visual analog scale.

Secondary Measures

  • Balance of effects
    • Time Frame: 24 hours
    • Based on Drug Liking VAS
  • Global effects
    • Time Frame: 24 hours
    • Overall Drug Liking VAS
  • Positive drug effects
    • Time Frame: 24 hours
    • High VAS
  • Positive drug effects
    • Time Frame: 24 hours
    • Good Drug Effects VAS
  • Negative drug effects
    • Time Frame: 24 hours
    • Bad Drug Effects VAS
  • Stimulant effects
    • Time Frame: 24 hours
    • Alertness/Drowsiness VAS
  • Stimulant effects
    • Time Frame: 24 hours
    • Agitation/Relaxation VAS
  • Other drug effects:
    • Time Frame: 24 hours
    • Hallucinations VAS
  • Other drug effects:
    • Time Frame: 24 hours
    • Detached VAS
  • Other drug effects:
    • Time Frame: 24 hours
    • Addiction Research Center Inventory (ARCI)
  • Other drug effects:
    • Time Frame: 12 hours
    • Drug Similarity VAS
  • Other drug effects:
    • Time Frame: 24 hours
    • Bowdle VAS
  • Cognitive and psychomotor effects
    • Time Frame: 24 hours
    • Divided Attention Test
  • Cognitive and psychomotor effects
    • Time Frame: 24 hours
    • Choice Reaction Time

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male or female subjects 18 to 55 years of age, inclusive. – Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2 and a minimum weight of at least 50.0 kg – Current recreational polydrug users who self-report to: – Have used stimulants (e.g., amphetamines, cocaine, methylphenidate) for non-therapeutic purposes (i.e., for psychoactive effects) at least 10 times in the past year and at least 1 time in the 8 weeks before Screening. – Have at least 10 lifetime uses of drugs (e.g., opioids, sedatives) from at least 1 other class other than alcohol. – Agree to use an approved method of contraception – Be willing and able to abide by all study requirements and restrictions – Additional criteria may apply Exclusion Criteria:

  • Substance or alcohol dependence within the past 2 years, – Clinically significant medical history or illness – Female subjects who have a positive pregnancy test, are currently pregnant or lactating, or who are planning to become pregnant within 30 days of last study drug administration. – Donation or loss of more than 500 mL whole blood within 30 days preceding the Screening visit. – Additional criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Biotie Therapies Inc.
  • Collaborator
    • Acorda Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael McDonnell, MD, Principal Investigator, INC Research Toronto

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.